بيكالوتاميد تيڤع ٥٠ ملغ إسرائيل - العربية - Ministry of Health

بيكالوتاميد تيڤع ٥٠ ملغ

teva pharmaceutical indust.ltd - bicalutamide 50 mg - tablets - bicalutamide - for the treatment of advanced prostate cancer in combination with lhrh analog therapy or surgical castration.

بيكالوتاميد تيڤع ١٥٠ ملغ إسرائيل - العربية - Ministry of Health

بيكالوتاميد تيڤع ١٥٠ ملغ

teva pharmaceutical indust.ltd - bicalutamide 150 mg - tablets - bicalutamide - in patients with locally advanced prostate cancer (t3-t4 any n m0 t1-t2 n+ m0) bicalutamide is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

دوﻧپيزيل تيڤع ١٠ ملغ إسرائيل - العربية - Ministry of Health

دوﻧپيزيل تيڤع ١٠ ملغ

teva pharmaceutical indust.ltd - donepezil hydrochloride 5 mg - tablets - donepezil - treatment of mild to moderately severe alzheimer's dementia.

ألفا D3 ٠.٢٥ مكغ كبسولات إسرائيل - العربية - Ministry of Health

ألفا d3 ٠.٢٥ مكغ كبسولات

teva pharmaceutical indust.ltd - alfacalcidol 0.25 mcg - capsules soft gelatin - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

ألفا D3 ١.٠ مكغ كبسولات إسرائيل - العربية - Ministry of Health

ألفا d3 ١.٠ مكغ كبسولات

teva pharmaceutical indust.ltd - alfacalcidol 1 mcg - capsules soft gelatin - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

ليتروزول تيڤع إسرائيل - العربية - Ministry of Health

ليتروزول تيڤع

teva pharmaceutical indust.ltd - letrozole 2.5 mg - tablets - letrozole - letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

أناستروزول تيڤع إسرائيل - العربية - Ministry of Health

أناستروزول تيڤع

teva pharmaceutical indust.ltd - anastrozole 1 mg - tablets - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

ريپاݘلينيد تيڤع ١ ملغ إسرائيل - العربية - Ministry of Health

ريپاݘلينيد تيڤع ١ ملغ

teva pharmaceutical indust.ltd - repaglinide 1 mg - tablets - repaglinide - treatment of type ii diabetes.

راﻣيپريل تيڤع ٥ ملغ إسرائيل - العربية - Ministry of Health

راﻣيپريل تيڤع ٥ ملغ

teva pharmaceutical indust.ltd - ramipril 5 mg - tablets - ramipril - - hypertension - congestive heart failure - reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.